Minerva Neurosciences | NERV - Actif À Court Terme





Actif À Court Terme Changement Date
Acadia Pharmaceuticals USD 1.22B 128.53M 2026-06
Adma Biologics USD 528.2M 17.03M 2026-06
ALKERMES USD 1.52B 164.26M 2026-06
Alterity Therapeutics Limited AUD 37.91M 15.92M 2025-12
AstraZeneca USD 27.97B 1.65B 2026-06
BioCryst Pharmaceuticals USD 484.68M 111.06M 2026-06
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Cipla INR 241.47B 7.71B 2026-03
Clal Biotechnology ILS 14.69M 1.95M 2023-12
Compugen USD 137.28M 10.74M 2026-03
CSL USD 11.85B 1000K 2025-12
Eli Lilly USD 64.67B 9.84B 2026-06
GlaxoSmithKline GBP 17.56B 202M 2026-06
Grifols EUR 5.96B 316.31M 2025-12
Halozyme Therapeutics USD 933.02M 70.01M 2026-06
Ionis Pharmaceuticals USD 2.49B 446.73M 2026-06
J&J USD 59.77B 601M 2026-06
Merck USD 36.68B 1.66B 2026-06
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Novartis USD 27.35B 744M 2026-06
Novavax USD 771.1M 79.72M 2026-06
Pfizer USD 41.36B 1.46B 2026-06
Roche Holding CHF 35.44B 3.29B 2026-06
Sanofi EUR 31.52B 1.36B 2026-06
Takeda JPY 3.15T 59.77B 2026-06
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12